Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 1094

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1094
---
 who comprised more than 10%
of the Company’s Branded revenues for the year ended December 31, 2023. There were no customers who comprised more than 10%
of ImprimisRx revenues for the years ended December 31, 2024 and 2023. As of December 31, 2024 and December 31, 2023, accounts
receivable from two customers and one customer accounted for 94%
and 80%,
respectively, of total consolidated accounts receivable.

The Company received its active pharmaceutical ingredients
from two and three main suppliers during the years ended December 31, 2024 and 2023, respectively. These suppliers collectively accounted
for 42%
and 64%
of active pharmaceutical ingredient purchases during the years ended December 31, 2024 and 2023, respectively.

NOTE
20. SUBSEQUENT EVENTS 

In February and March 2025, the Company issued 2,743
shares of common stock and received proceeds of $23,000
upon the exercise of options to purchase 2,743
shares of common stock with exercise prices between $6.85 to
$15.17
per share.

In January 2025, the Company issued 29,214 shares
of its common stock underlying RSUs held by a director that ceased providing services to the Company. The RSUs had previously vested,
including 8,046 RSUs during the year ended December 31, 2024, but the issuance and delivery of the shares were deferred until
the director ceased providing services to the Company.

F-46